title: A tumor-specific microRNA signature predicts survival in clear cell renal cell carcinoma.
abstract: OBJECTIVE
  Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancers in adults, and microRNAs (miRNAs) differentially expressed in ccRCC tumors have been identified and proposed to predict prognosis. In the present study, we comprehensively analyzed the genome-wide miRNA expression profiles in ccRCC, with the aim to generate a tumor-specific miRNA signature of prognostic values.
  
  
  METHODS
  The miRNA profiles in tumor and the adjacent normal tissue were analyzed, and the association of the differentially expressed miRNAs with patient survival was examined with univariate Cox regression analysis. Finally, a tumor-specific miRNA signature was generated and examined with Kaplan-Meier survival, univariate, and multivariate Cox regression analyses.
  
  
  RESULTS
  A total of 147 miRNAs were found differentially expressed between tumor and matched non-tumor tissues from 58 ccRCC patients. The prognostic values of these differentially expressed miRNAs were subsequently analyzed in the 411 ccRCC patients, and 22 miRNAs were found significantly correlated with patient survival. Finally, a tumor-specific miRNA signature of 22 miRNAs was generated and validated as an independent prognostic parameter.
  
  
  CONCLUSIONS
  A tumor-specific miRNA signature consisting of 22 miRNAs was identified and validated as an independent prognostic factor, which could serve as a novel biomarker for ccRCC prognostication and help in predicting treatment outcome.
authors: Department of Urology, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, China.
authors: Yu-Zheng
authors: YZ
authors: Ge
authors: Ran
authors: R
authors: Wu
authors: Hui
authors: H
authors: Xin
authors: Meng
authors: M
authors: Zhu
authors: Tian-Ze
authors: TZ
authors: Lu
authors: Hao
authors: H
authors: Liu
authors: Zheng
authors: Z
authors: Xu
authors: Peng
authors: P
authors: Yu
authors: You-Cai
authors: YC
authors: Zhao
authors: Ming-Hao
authors: MH
authors: Li
authors: Zhi-Kai
authors: ZK
authors: Hu
authors: Yan
authors: Y
authors: Zhao
authors: Bing
authors: B
authors: Zhong
authors: Xiao
authors: X
authors: Xu
authors: Liu-Hua
authors: LH
authors: Zhou
authors: Lu-Wei
authors: LW
authors: Xu
authors: Jian-Ping
authors: JP
authors: Wu
authors: Wen-Cheng
authors: WC
authors: Li
authors: Jia-Geng
authors: JG
authors: Zhu
authors: Rui-Peng
authors: RP
authors: Jia
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality*; D015331:Cohort Studies; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality*; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D046228:Microarray Analysis; D008875:Middle Aged; D009928:Organ Specificity / Q000235:genetics; D011379:Prognosis; D016019:Survival Analysis; D059467:Transcriptome
chemical_list: D035683:MicroRNAs
references: J Cancer Res Clin Oncol. 2014 Aug;140(8):1421-8
references: 24752340
references: Cancer Biol Ther. 2014 Mar 1;15(3):329-41
references: 24351440
references: Eur Urol. 2011 May;59(5):671-81
references: 21296484
references: Clin J Am Soc Nephrol. 2012 Sep;7(9):1528-33
references: 22580786
references: Urol Oncol. 2014 Jan;32(1):41.e1-9
references: 24035473
references: Urology. 2010 Apr;75(4):835-41
references: 20035975
references: Cancer Inform. 2008;6:9-15
references: 19259398
references: Carcinogenesis. 2012 Jun;33(6):1126-33
references: 22491715
references: J Cancer Res Clin Oncol. 2010 Jun;136(6):855-62
references: 19921256
references: Mol Oncol. 2012 Dec;6(6):590-610
references: 23102669
references: Cancer Cell. 2008 Jan;13(1):48-57
references: 18167339
references: Urology. 2010 Sep;76(3):521-7
references: 20472270
references: Cell. 2013 Apr 25;153(3):516-9
references: 23622238
references: Nucleic Acids Res. 2014 Jan;42(Database issue):D68-73
references: 24275495
references: Oncogene. 2010 Sep 2;29(35):4914-24
references: 20562915
references: PLoS One. 2012;7(5):e35661
references: 22623952
references: J Cancer Res Clin Oncol. 2014 Aug;140(8):1295-304
references: 24802708
references: Oncogene. 2010 Oct 21;29(42):5724-8
references: 20676129
references: Eur Urol. 2006 May;49(5):798-805
references: 16442207
references: Semin Cancer Biol. 2013 Feb;23(1):10-7
references: 22750267
references: J Cancer Res Clin Oncol. 2015 Mar;141(3):431-41
references: 25245053
references: N Engl J Med. 2004 Apr 29;350(18):1828-37
references: 15115829
references: Eur Urol. 2010 Sep;58(3):398-406
references: 20633979
references: PLoS One. 2012;7(6):e38298
references: 22745662
references: Eur Urol. 2014 Nov;66(5):936-48
references: 25047176
references: Eur J Cancer. 2014 Jul;50(10):1758-1765
references: 24793999
references: Nature. 2008 Sep 4;455(7209):58-63
references: 18668040
references: Nature. 2013 Jul 4;499(7456):43-9
references: 23792563
references: Curr Opin Genet Dev. 2012 Feb;22(1):50-5
references: 22402447
references: Int J Urol. 2009 May;16(5):432-43
references: 19453547
references: Br J Cancer. 2013 Nov 12;109(10):2646-53
references: 24129247
references: J Urol. 2011 Sep;186(3):1077-83
references: 21784468
references: Lancet Oncol. 2012 Jun;13(6):633-41
references: 22560814
references: Cell. 2005 Jan 14;120(1):15-20
references: 15652477
references: Eur Urol. 2015 Jan;67(1):85-97
references: 24857407
references: BMC Syst Biol. 2010 Apr 27;4:51
references: 20420713
references: Eur J Cancer. 2013 Apr;49(6):1374-403
references: 23485231
references: Cell. 2004 Jan 23;116(2):281-97
references: 14744438
references: Oncotarget. 2012 Jan;3(1):44-57
references: 22294552
references: Nature. 2008 Sep 4;455(7209):64-71
references: 18668037
references: Nat Rev Cancer. 2006 Nov;6(11):857-66
references: 17060945
references: CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
references: 24399786